CJC 1295 (no DAC)

Molecular Overview:

CJC-1295 (no DAC) is a synthetic GHRH analog investigated for its interaction with endocrine signaling pathways and growth-hormone-associated regulatory processes. Experimental studies have explored its effects on pituitary signaling and peptide-receptor communication in laboratory models.

Key areas of investigation include:

• Growth-hormone-releasing hormone signaling
• Pituitary-associated communication pathways
• Endocrine system regulatory mechanisms
• Metabolic signaling pathway analysis
• Peptide-receptor interaction research

These areas position CJC-1295 (no DAC) as a compound of interest in endocrine biology, peptide signaling, and metabolic research.

Mechanisms of Action (Investigational):

GHRH Receptor Interaction:

CJC-1295 (no DAC) has been evaluated for its interaction with receptors associated with growth-hormone-releasing hormone signaling.

Endocrine Signaling Activity:

Research has explored the peptide’s effects on pituitary-associated communication pathways in controlled laboratory environments.

Hormonal Regulatory Pathways:

Studies suggest potential involvement in endocrine-regulatory signaling processes relevant to metabolic research models.

Observed Research Effects (Non-Clinical):

Findings from experimental models have suggested potential associations with:
• Modulation of endocrine signaling pathways
• Growth-hormone-associated communication activity
• Peptide-receptor signaling interactions
• Metabolic regulatory pathway responses
• Pituitary signaling activity

These observations are preliminary and limited to controlled research environments.

Common Research Applications:

CJC-1295 (no DAC) is utilized in laboratory investigations involving:
• Endocrine signaling pathway analysis
• Growth-hormone-related research models
• Metabolic regulation studies
• Peptide-receptor communication investigations
• Experimental pituitary signaling research
• Molecular endocrine biology studies

Legal Disclaimer:

This product is intended for research use only. Not for human consumption, medical use, or veterinary application. This compound has not been evaluated by the U.S. Food and Drug Administration for safety or efficacy. All use must comply with applicable laws and regulations.

All products sold on this site are for research and development use only. They are not intended for human or animal use.
 

The statements on this website have not been evaluated by the US Food and Drug Administration (FDA). Our products and content are not intended to diagnose, treat, cure, or prevent any disease.

Tides Peptides is a chemical supplier, not a compounding pharmacy or a chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act.

• Peptide Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

• Molecular Formula: C152H252N44O42

• Molecular Weight: 3367.9 g/mol

1. What is CJC-1295 (no DAC) and why does it matter?

CJC-1295 (no DAC) is a synthetic peptide investigated in research models related to endocrine signaling and growth-hormone-associated pathways.

• Studied in relation to GHRH receptor activity
• Evaluated for interactions with endocrine communication systems
• Utilized in metabolic and peptide-signaling research models

2. What are the benefits of CJC-1295 (no DAC)?

• Associations with endocrine signaling modulation
• Observations involving peptide-receptor interactions
• Interactions with metabolic regulatory pathways
• Effects in pituitary signaling research models
• Activity in growth-hormone-associated pathway studies

These findings are limited to preclinical and laboratory research.

3. What is CJC-1295 (no DAC) used for?

Endocrine Research:

• Growth-hormone signaling investigations
• Pituitary communication pathway studies
• Experimental endocrine regulation models

Cellular & Molecular Research:

• Peptide-receptor interaction analysis
• Metabolic pathway investigations
• Molecular endocrine biology research

White Papers:

https://pubmed.ncbi.nlm.nih.gov/17200197/
(Study evaluating CJC-1295 and growth-hormone-releasing hormone analog activity in research models.)

https://pubmed.ncbi.nlm.nih.gov/15249655/
(Research examining GHRH analogs and endocrine signaling pathways.)

https://pubmed.ncbi.nlm.nih.gov/8784072/
(Study involving growth-hormone-releasing hormone receptor interactions and peptide signaling.)

https://pubmed.ncbi.nlm.nih.gov/16464951/
(Research discussing modified GHRH analogs and pituitary-associated communication.)

https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/
(Review of GHRH analog biology, endocrine signaling, and metabolic regulation pathways.)

https://pubmed.ncbi.nlm.nih.gov/12531895/
(Experimental study evaluating peptide-receptor interactions associated with GHRH analogs.)

https://pubmed.ncbi.nlm.nih.gov/10861339/
(Research examining endocrine signaling and metabolic pathway modulation related to GHRH peptides.)